Dr. Louis Bessette graduated from medical school and completed his residency in Internal Medicine and Rheumatology at Laval University. He trained as a fellow in clinical research at the Multipurpose Arthritis Center, Brigham and Women’s Hospital in Boston and received a master’s degree in epidemiology from the Harvard School of Public Health.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University, assistant professor at Laval University’s School of Medicine. Since 2014, he has been Chief of the Rheumatology Department at the CHU de Québec-Laval University. His main research interests are rheumatoid arthritis and osteoporosis, as well as the quality of life aspects and pharmacoeconomic studies related to these diseases.
Dr. Bessette is the principal investigator of the CATCH study in Quebec City (Canadian Early Arthritis Cohort Study). CATCH is a Canadian multicentre research program that aims at improving the quality of care for people with early inflammatory arthritis. Over 2,000 people are participating in our investigator-initiated research program across Canada (100 subjects in Quebec City). This is the only Canada-wide early arthritis cohort that follows people with new onset inflammatory or rheumatoid arthritis over time to examine the course of their disease and their response to the treatments provided by their healthcare team.
He is co-investigator of the Group for Early Arthritis Research (GEAR). GEAR is a multidisciplinary team of the CHU de Québec-Laval University composed of clinicians and clinical researchers in the field of rheumatology. A model for an early arthritis clinic was put in place in 2014 to give better and earlier access to patients who suffer from rheumatic conditions. Other objectives are to collect clinical data and bio specimens on patients with early arthritis to better understand disease progression and its complications. Collecting these data and bio specimens will provide information on the population in the CHU de Québec-Laval University catchment area, and allow to elaborate strategies to improve patient care and prevent comorbid conditions in patients with early arthritis.
Dr. Bessette is co-director for the CaMOS Quebec City Centre, a large Canadian epidemiologic study in osteoporosis. He is also co-investigator of the Recognizing Osteoporosis and its Consequences in Quebec (ROCQ) Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women aged 50 years and over.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.Journal Article
Arthritis Rheumatol, 71 (11), pp. 1788-1800, 2019.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.Journal Article
Ann Rheum Dis, 78 (11), pp. 1454-1462, 2019, ISSN: 0003-4967.
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.Journal Article
Rheumatology (Oxford), 2019, ISSN: 1462-0324.
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.Journal Article
Rheumatology (Oxford), 2019, ISSN: 1462-0324.
Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort.Journal Article
Clin Exp Rheumatol, 37 (4), pp. 561-565, 2019, ISSN: 0392-856X.
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.Journal Article
Arthritis Res Ther, 21 (1), pp. 138, 2019, ISSN: 1478-6354.
Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.Journal Article
Osteoporos Int, 30 (4), pp. 721-740, 2019, ISSN: 0937-941X.
Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis.Journal Article
Scand J Rheumatol, 48 (2), pp. 121-127, 2019, ISSN: 0300-9742.
Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.Journal Article
Ther Adv Musculoskelet Dis, 11 , pp. 1759720X19831151, 2019, ISSN: 1759-720X.
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.Journal Article
Lancet, 391 (10139), pp. 2503-2512, 2018, ISSN: 0140-6736.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche en arthrite de l'Université Laval, Subvention, Institutionnel - BDR, BDR - Entités de recherche en émergence, from 2019-01-01 to 2020-01-31
Recently finished projects
- Canadian Network for Advanced interdisciplinary Methods for Prospective Studies of Drug Safety and Effectiveness., Subvention, Instituts de recherche en santé du Canada, Subvention d'équipe : Centre de collaboration pour les études prospectives du RIEM, from 2014-09-01 to 2019-08-31
- Soutien du programme de recherche en rhumatologie, Subvention, Fondation du CHU de Québec, from 2017-03-31 to 2019-03-31